AMGN Stock Analysis & Forecast (2026)

Amgen Inc. Healthcare Drug Manufacturers - General
$346.36
Current Price
76%
Buy
View Plans
Data refreshed: April 22, 2026

Key Financial Metrics

Market Cap
$186.71B
P/E Ratio (TTM)
24.3x
P/E Forward
14.8x
Revenue Growth
8.6%
Gross Margin
70.8%
Net Margin
21.0%
Return on Equity
106.1%
Debt/Equity
6.40

AI Analysis Summary

Amgen Inc. (AMGN) is a Healthcare company in the Drug Manufacturers - General industry with a 76% Buy Score. Key strengths include Gross Margin (70.8%), Net Margin (21.0%), Return on Equity (106.1%). Areas to watch: Debt/Equity (6.40). Our AI evaluates 8 fundamental categories including revenue growth, margin quality, balance sheet strength, cash flow generation, return on capital, and valuation metrics.

Revenue Growth: Moderate Gross Margin: Excellent Net Margin: Excellent Return on Equity: Excellent Debt/Equity: High Risk

This analysis is generated by StrongBuyAnalytics AI using publicly available financial data from SEC filings, earnings reports, and market feeds. It is not personalized investment advice. See our methodology and disclaimer.

AMGN Fundamental Analysis Report
PDF Report Preview
76%
Strong Buy Score
  • 8 Fundamental Categories Analyzed
  • Revenue & Growth Trends
  • Margin & Profitability Analysis
  • Balance Sheet Strength
  • Cash Flow Quality
  • Valuation Assessment
  • AI-Powered Investment Insights
Get Your Free AMGN Report

How It Works: AI Stock Analysis in 60 Seconds

See how our AI analyzes AMGN fundamentals to generate buy/sell signals and Strong Buy Scores.

Why AMGN Has a 76% Score

Our AI evaluates Amgen Inc.'s fundamentals across multiple dimensions. Here is what is driving the current Buy rating:

Recent Catalysts for AMGN

Key developments and data points that may impact Amgen Inc.'s trajectory:

Earnings grew 112.1% — accelerating profitability could drive re-rating.
Analyst consensus recommendation: Hold.
Institutional ownership at 85.4% — strong smart-money backing.
Short ratio of 5.4 days to cover — elevated short interest could fuel a squeeze on positive news.
Dividend yield of 2.92% provides income while you wait for capital appreciation.

AMGN vs. Peers

How Amgen Inc. stacks up against comparable Healthcare companies on key metrics:

Ticker Price Market Cap P/E Rev Growth Net Margin ROE
AMGN $346.36 $186.71B 24.3x 8.6% 21.0% 106.1%
JNJ $227.02 $547.10B 20.6x 9.9% 21.8%
UNH $353.72 $321.06B 26.8x 12.3% 2.7% 12.5%
PFE $27.27 $155.15B 20.1x -1.2% 12.4% 8.9%
MRK $112.73 $278.71B 15.5x 5.0% 28.1% 36.9%

Main Risks for AMGN Investors

Every investment carries risk. Here are the specific risk factors our analysis identified for Amgen Inc.:

Debt/Equity (6.40)
Low beta of 0.47 suggests limited upside participation in bull markets.
Short interest is elevated with a 5.4-day cover ratio, indicating bearish bets against the stock.
High leverage amplifies downside risk if revenue softens or interest rates rise.

Generate the full PDF report for a detailed risk-reward framework and bear-case scenarios.

AMGN Balance Sheet & Cash Flow

A snapshot of Amgen Inc.'s financial health based on the most recent filings:

Total Cash
$9.13B
Total Debt
$55.44B
Current Ratio
1.14
FCF Yield
4.0%
EBITDA
$16.62B
Operating Margin
30.5%

Data sourced from the latest SEC filings. Generate the full PDF report for detailed balance sheet and cash flow commentary.

AMGN Valuation Snapshot

Trailing P/E
24.3x
Fairly valued
Forward P/E
14.8x
Earnings growth expected
Price / Book
21.6x
High intangible value
PEG Ratio
2.35
Expensive vs growth
Analyst Target (Mean)
$352.73
Range: $200 – $432
Dividend Yield
2.92%
5Y avg: 3.06%
52-Week Price Range — AMGN is trading at 65% of its range
$261.43 (52W Low) $391.29 (52W High)

Is AMGN a Buy Right Now?

Based on our AI-powered fundamental analysis, AMGN has a Strong Buy Score of 76%, earning a "Buy" rating. This score synthesizes 8 key financial metrics to provide an objective investment signal.

Strong Buy Signal

Amgen Inc. demonstrates robust fundamentals across multiple categories. Key strengths include Gross Margin (70.8%) and Net Margin (21.0%). The stock shows characteristics typically associated with outperformers.

AMGN AI Buy & Sell Signals Explained

Our AI analyzes Amgen Inc.'s financial statements to generate buy/sell signals based on quantitative metrics, not market sentiment or news headlines. Here's what drives the 76% score:

  • Revenue Growth: 8.6% year-over-year (positive)
  • Gross Margin: 70.8% (strong pricing power)
  • Net Margin: 21.0% (highly profitable)
  • Return on Equity: 106.1% (excellent capital efficiency)

Generate the full PDF report for complete category-by-category scoring and AI-powered investment recommendations.

Key Support / Demand Zones

Technical traders can view real-time demand and supply zones for AMGN on our Demand Zones page. These zones identify key price levels where institutional buying or selling has historically occurred.

With AMGN currently trading at $346.36, our system monitors proximity to these critical levels and can alert you when the stock approaches support or resistance zones.

Subscribe to demand zone alerts to receive real-time notifications when AMGN reaches key technical levels.

Earnings & Revenue Outlook

Amgen Inc. operates in the Healthcare sector, specifically in Drug Manufacturers - General. Understanding earnings trends is crucial for forecasting AMGN's trajectory.

Current revenue growth of 8.6% exceeds the average company.

Visit our Earnings Calendar to track upcoming AMGN earnings dates and historical beat/miss patterns. Sign up for earnings alerts to get notified before announcements.

AMGN Stock Forecast (Next 3–12 Months)

Our AI projects AMGN's trajectory based on current fundamentals and historical patterns. With a 76% Strong Buy Score, here's what the data suggests:

Bullish Outlook: Amgen Inc. shows strong fundamental momentum. Net margins of 21.0% indicate pricing power and operational efficiency. Stocks with similar profiles have historically outperformed over 12-month periods.

For a complete 12-month price forecast with specific bull/bear scenarios, generate the full PDF report.

Valuation Metrics (P/E, Growth, Margins)

Understanding valuation is critical for determining if AMGN is fairly priced. Here's the current snapshot:

  • Market Capitalization: $186.71B
  • P/E Ratio (TTM): 24.3x (fairly valued)
  • Forward P/E: 14.8x (based on analyst estimates)
  • Debt/Equity: 6.40 (higher leverage)

Our AI weighs these metrics against growth rates and margin quality to determine if AMGN offers compelling risk-adjusted returns at current prices.

Bull Case for AMGN

Here's why investors are bullish on Amgen Inc.:

  • Gross Margin (70.8%)
  • Net Margin (21.0%)
  • Return on Equity (106.1%)

With a 76% Strong Buy Score, the bull case is well-supported by current fundamentals. The stock exhibits characteristics of quality compounders that tend to outperform long-term.

Bear Case & Risks for AMGN

Every investment carries risk. Here are potential concerns for AMGN investors:

  • Debt/Equity (6.40)

The full PDF report includes a detailed bear case analysis with specific risk ratings for each category.

Summary / 12-Month Outlook

AMGN Summary: Amgen Inc. earns a 76% Buy Score based on AI analysis of fundamental data. Trading at $346.36 with a $186.71B market cap, the stock shows strong fundamentals supporting a bullish 12-month outlook.

Bull Case: Gross Margin (70.8%), Net Margin (21.0%)

Watch: Debt/Equity (6.40)

For the complete analysis with specific price considerations, growth projections, and AI-powered buy/hold/sell recommendations, generate your free AMGN PDF report.

Learn More About Stock Analysis

Deepen your understanding of the concepts used in this AMGN analysis:

Fundamental Analysis Guide

Learn how to evaluate stocks using financial statements and key metrics.

Understanding P/E Ratio

What P/E ratio tells you about a stock's valuation and growth expectations.

Return on Equity (ROE)

Why ROE matters for stock selection and how to interpret it.

Stock Valuation Methods

Compare DCF, P/E, and other approaches to value stocks like AMGN.

What Are Demand Zones?

Find key support and resistance levels for AMGN and other stocks.

How to Read Earnings Reports

Understand earnings per share, revenue surprises, and guidance.

Related Tools for AMGN

Demand Zone Analyzer AMGN Live Chart AMGN SEC Filing News Earnings Calendar Institutional Ownership Sector Scanner Average Down Calculator

AMGN SEC Filing News

Latest SEC filings for AMGN explained in plain English — insider buys/sells (Form 4), proposed sales (Form 144), material events (8-K), and quarterly & annual reports.

Loading recent SEC filings…
View all AMGN SEC Filing News →

Frequently Asked Questions about AMGN

Is AMGN a good buy right now?
AMGN currently has a Strong Buy Score of 76% (Buy). Based on AI analysis of fundamentals, AMGN shows strong buy signals with solid revenue growth, margins, and return metrics. Generate a free PDF report for specific buy/hold/sell recommendations.
What is the AMGN stock forecast for 2026?
Our AI forecasts AMGN based on current fundamentals: revenue growth of 8.6%, net margin of 21.0%, and P/E of 24.3x. The 76% Strong Buy Score reflects our outlook combining growth trajectory, margin quality, and valuation. See the full 12-month projection in your PDF report.
What are key support and resistance levels for AMGN?
View real-time AMGN demand zones (support) and supply zones (resistance) on our Demand Zones page. With AMGN currently at $346.36, you can see how close the stock is to key technical levels. Subscribe to get alerts when AMGN approaches these zones.
How do AMGN fundamentals compare to peers?
Amgen Inc. operates in the Healthcare sector. Key metrics for peer comparison: Gross margin 70.8%, ROE 106.1%, Debt/Equity 6.40. The 76% Strong Buy Score factors in how these metrics stack up against industry averages. Data is refreshed daily.
Is the AMGN analysis PDF report free?
Yes! Your first AMGN fundamental analysis report is completely free with no credit card required. The PDF includes the full Strong Buy Score breakdown, all 8 fundamental categories analyzed, AI-powered insights, and specific investment recommendations. Additional reports are available through our subscription plans starting at $24/month.
What is Amgen Inc.'s market cap and P/E ratio?
Amgen Inc. (AMGN) has a market cap of $186.71B and a trailing P/E ratio of 24.3x (forward P/E: 14.8x). These valuation metrics are key factors in our Strong Buy Score calculation. See all metrics in the PDF report for comprehensive valuation analysis.

This AMGN analysis is for educational and informational purposes only and does not constitute financial advice. All data is sourced from public filings and market feeds. Past performance does not guarantee future results. Read our full disclaimer.